Howard Community College Named Among Nation's Top 200 Institutions Eligible for Prestigious $1 Million Aspen Prize

FIRST COMMUNITY CORP /SC/ (FCCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e26306_ex99-1.htm News Release For Release July 22, 2026 9:00 A.M. Contact: Michael C. Crapps, Chief Executive Officer and President D. Shawn Jordan, Executive Vice President & Chief Financial Officer or Robin D. Brown, Executive Vice President & Chief Marketing Officer

Adobe Inc. (ADBE) named Anil Chakravarthy as its next CEO, effective December 1, 2026. Shantanu Narayen will transition to executive chair. Stifel reiterated a Hold rating with a $200 price target, implying 25% downside. Q2 revenue was $6.62B, up 13% YoY. The CFO role remains interim. Hedge funds slightly reduced positions. Next earnings report is on September 10.

Michael Burry sold his stake in Alibaba (BABA), calling its shares overvalued and objecting to its $10.2B share sale for AI funding. He reinvested in JD.com (JD), citing easing competition in China's delivery market. Alibaba's hedge fund holdings decreased slightly, while JD.com's saw a minor increase.

The US approved a $5 billion arms sale to Saudi Arabia, including 10,000 guidance kits and bombs. The State Department cleared the deal, citing national security interests. Boeing is the principal contractor. This follows escalating tensions between the US and Iran, with recent strikes and retaliations.

John Ternus became Apple's CEO on September 1, 2026. He will oversee his first product event on September 9, featuring a foldable iPhone, new Apple Watches, and the launch of iOS 27 with Google's Gemini AI. Ternus, a hardware engineer, faces challenges in AI development and investor skepticism about Apple's AI strategy. Apple reported record revenue of $109.4 billion in Q2 2026 but saw a 9.4% stock drop due to weak guidance and AI concerns.

Novartis and Ionis Pharmaceuticals reported that their experimental heart drug, pelacarsen, failed to reduce the risk of major heart attacks and strokes in a late-stage trial. The drug, targeting genetically inherited cholesterol Lp(a), lowered Lp(a) levels but did not meet its primary endpoint. Novartis shares fell 5%, and Ionis shares dropped 12% in aftermarket trading. The companies plan to present full trial data at an upcoming medical congress.